XENE · Xenon Pharmaceuticals Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Xenon reported a productive Q2 2026, completing a successful pre-NDA meeting and keeping the azetukalner FOS NDA submission on track for Q3 2026, while advancing Phase 3 programs in epilepsy, neuropsychiatry, and a growing pain pipeline (XEN1701, XEN1120, and a new NaV1.7 candidate XEN1720), with $1.2 billion in cash funding operations into 2029 despite a wider net loss.
- + Strong cash position of $1,245.1 million, with runway into 2029 to support launch and pipeline.
- + Pain pipeline expanded with Phase 1 initiation of second NaV1.7 candidate XEN1720 alongside advancing XEN1701 and XEN1120.
- + XTOL-2 Phase 3 data continues to receive positive HCP feedback, including best-in-class placebo-adjusted efficacy.
- + Three Phase 3 azetukalner studies advancing in neuropsychiatry (MDD/BPD), with X-NOVA2 MDD topline data expected H1 2027.
- − Net loss widened to $110.7M in Q2 2026 vs $84.7M in Q2 2025.
- − R&D expenses rose to $99.2M in Q2 2026 vs $75.0M in Q2 2025.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XENE
this stock
Xenon Pharmaceuticals Inc.
|
$3.58B | -17.0% | -82.8% | — | 6.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XENE | +1.7% | -38.0% | -36.5% | -38.2% | -17.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.4% | -38.1% | -48.7% | -37.7% | -28.9% |